The consistency of findings across SGLT2 inhibitors and GLP-1 receptor agonists highlights that their cardiovascular benefits extend well beyond glucose control, offering a compelling biological rationale for their integration into standard care for patients with type 2 diabetes and cardiovascular risk. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.